OraSure Technologies, Inc. (OSUR)
| Market Cap | 407.31M |
| Revenue (ttm) | 242.80M |
| Net Income (ttm) | -46.74M |
| Shares Out | 76.85M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 192,545 |
| Open | 5.23 |
| Previous Close | 5.23 |
| Day's Range | 5.19 - 5.45 |
| 52-Week Range | 4.73 - 13.57 |
| Beta | -0.35 |
| Analysts | Buy |
| Price Target | 11.35 (+114.2%) |
| Earnings Date | May 10, 2022 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebol...
Financial Performance
In 2021, OSUR's revenue was $233.67 million, an increase of 36.08% compared to the previous year's $171.72 million. Losses were -$23.00 million, 54.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 11.35, which is an increase of 114.15% from the latest price.
News
InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants
BETHLEHEM, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced tod...
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue
InteliSwab ® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production
OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 first quarter financial results and certain bu...
OraSure Technologies' Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for th...
BETHLEHEM, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced t...
OraSure Technologies' Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Micr...
BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced t...
OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics an...
Board Continues Search for Permanent CEO
OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up
Total 2021 revenue of $233.7 million, up 36% year-over year
OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain ...
OraSure said its rapid COVID-19 tests can now be used in children
Shares of OraSure Technologies Inc. OSUR, +5.09% gained 2.2% in premarket trading on Monday after the company said its COVID-19 rapid tests have now been authorized for children between the ages of 2 an...
InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab...
Data Demonstrates InteliSwab ® is Accurate, Easy to Use, and Well Accepted by Children
OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe
BETHLEHEM, Pa., Jan. 25, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced t...
InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants
BETHLEHEM, Pa., Jan. 13, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced to...
OraSure's CEO Resigns, Commences Review Of Strategic Alternatives
OraSure Technologies Inc (NASDAQ: OSUR) expects Q4 FY21 revenue at the low end of the Company's guidance range of approximately $60 million. The Company anticipates total InteliSwab revenue of approxima...
OraSure Technologies Announces Actions to Enhance Stockholder Value
Provides Preliminary 4Q21 Financial Outlook
OraSure Technologies Announces 2022 Annual Meeting Date
BETHLEHEM, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a...
OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus
Company to Ring Nasdaq Closing Bell and Host Panel Discussions on HIV in New York City Company to Ring Nasdaq Closing Bell and Host Panel Discussions on HIV in New York City
Rapid Covid-19 tests in high demand ahead of Thanksgiving
CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.
OraSure Technologies to Present at Upcoming Investor Conferences
BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical...
OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M.
BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced to...
OraSure Technologies Appoints Two New Members to the Board of Directors
New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience
OraSure Q3 Sales, Without COVID Related Products, Jump 37%; Guides FY21 Sales Below Consensus
OraSure Technologies Inc (NASDAQ: OSUR) reported Q3 revenues of $53.92 million, +12% Y/Y, beating the consensus of $47.48 million. Excluding COVID-19 product-related sales, revenues grew by 37%, demonst...
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -320.00% and 13.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning t...
Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET
FDA Authorizes OraSure's COVID-19 Rapid Tests For OTC Single-Use
The FDA has amended OraSure Technologies Inc's (NASDAQ: OSUR) Emergency Use Authorization (EUA) for its InteliSwab COVID-19 rapid tests to only require one test for symptoms of COVID-19. Related Link: ...